- Home
- EVAX vs LITS Comparison
EVAX vs LITS Comparison
Compare EVAX & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVAX | LITS |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 25.7M |
| IPO Year | 2020 | 2003 |
Fundamental Metrics
Financial Performance| Metric | EVAX | LITS |
|---|---|---|
| Price | $3.25 | $1.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | 50.5K | ★ 722.5K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $328.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.77 | $0.69 |
| 52 Week High | $12.15 | $2.97 |
Technical Indicators
Market Signals| Indicator | EVAX | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 71.02 |
| Support Level | $2.92 | $0.86 |
| Resistance Level | $3.33 | $1.65 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 87.14 | 86.24 |
Price Performance
Historical ComparisonAbout EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.